Diversity and race-concordant relationships contribute to improved patient experiences and outcomes. In contrast, the representation of underrepresented in medicine (URiM) individuals in different medical specialties is declining. The essential pathway to improving diversity within the future workforce centers around the inclusion of a diverse cohort of medical students. We aimed to examine the diversity of medical school applications and admissions across sex, race and ethnicity over the past decade. This study used data from the Association of American Medical Colleges from 2015 to 2024. URiM individuals refer to minority populations that are underrepresented in the medical profession, including Black, Hispanic, American Indian or Alaska Native (AIAN), and Native Hawaiian or Other Pacific Islander (NHPI). Diversity representation was measured using the representation index. There was an increasing trend in medical school applicants among females but a decreasing trend among males. The number of Asian female applicants increased significantly (51.33%), while the numbers of Black (29.74%) and Hispanic (14.98%) female applicants also showed notable upward trends. Matriculation rates for Black females (mean: 33.64%; SD: 2.28%) and overall URiM females (mean: 35.94%; SD: 2.02%) have consistently remained below White females (mean: 44.22%; SD: 2.66%), Asian females (mean: 43.57%; SD: 2.59%), and the national average for females (mean: 40.96%; SD: 2.05%) over the past decade. The findings indicate that all racial and ethnic groups were underrepresented among both applicants and matriculants over the last decade, with the exception of Asian individuals. The representation index between matriculants and applicants among Black females (-1.46 vs. -1.19; P < 0.001) is widening, which may help explain the underrepresentation discrepancy for overall URiM females (-2.09 vs. -1.83; P < 0.001). This study highlights both progress and persistent challenges in achieving racial and ethnic diversity in U.S. medical education. While female and URiM applicant numbers have increased, matriculation disparities remain, especially among Black and URiM females. The widening representation gap between applicants and matriculants underscores structural barriers that continue to hinder equity in medical school admissions. A more inclusive physician workforce should begin with meaningful reform in how future doctors are recruited, supported, and selected.

Introduction: Lecanemab is the second anti-amyloid- β monoclonal antibody to receive FDA approval for the treatment of early Alzheimer’s disease (AD), following aducanumab. Unlike aducanumab, which faced restricted Medicare coverage, lecanemab received traditional approval in 2023, resulting in broader access through Medicare. Despite these developments, the comparative cost-effectiveness of lecanemab and aducanumab has not been fully established. This study aimed to assess whether lecanemab is more cost-effective than aducanumab in the management of early AD. Methods: An indirect comparison of cost-effectiveness was performed due to the absence of head-to-head randomized controlled trials. A five-state Markov model was constructed from the perspective of the US healthcare system with a lifetime horizon and a 1-year cycle length. Model outcomes included life-years (LYs), quality-adjusted life-years (QALYs), and costs, all discounted at an annual rate of 3%. Incremental cost-effectiveness ratios (ICERs) were calculated and compared with established willingness-to-pay (WTP) thresholds. One-way sensitivity analyses identified key drivers of model uncertainty, and a probabilistic sensitivity analysis (PSA) with 1,000 Monte Carlo simulations tested the robustness of the findings. Results: The incremental cost of the lecanemab group compared to the aducanumab group was $30,018.97, with an increase in quality-adjusted life-years (QALYs) of 0.25, resulting in an ICER of $121,678.49 per QALY gained. The result of the one-way sensitivity analysis showed that the utility of the state of mild dementia due to AD had the most important effects on the ICER of the lecanemab group compared to the aducanumab group. The probabilistic sensitivity analysis showed that lecanemab was more cost-effective than aducanumab across various WTP thresholds. Conclusion: Our findings suggest that lecanemab provides greater value than aducanumab; however, at current list prices, neither drug is cost-effective compared with the standard of care. Price reductions are necessary to improve affordability, particularly for lecanemab, which is more widely covered by Medicare. Policy implications remain significant, as under the Inflation Reduction Act (IRA), biologics such as lecanemab are exempt from Medicare price negotiations for 13 years post-approval, limiting short-term opportunities for cost adjustment.

Using 2016–2023 data from the Behavioral Risk Factor Surveillance System (BRFSS), this study examined trends in self-reported past-month poor mental health (≥ 1 day) among individuals using cannabis and disparities in subgroups. From 2016 to 2023, the prevalence of self-reported past-month poor mental health (≥ 1 day) among those using cannabis increased from 54.54% to 67.88%. Women reported higher rates than men (77.08% vs. 60.14%). Young adults (25–34) showed the largest increase (from 51.42% to 77.67%). Hispanics (69.17%) exhibited the highest prevalence in 2023. Findings underscore the need for mental health screening and targeted counseling as cannabis legalization expands.

This study examined national trends in poor mental health among cannabis users and explored disparities by consumption mode, age, sex, races and ethnicities. Between 2016 and 2023, the prevalence among cannabis users increased from 54.54% to 67.88%. Prevalence was highest among vaping users (76.96%) and dabbing users (77.18%). Females reported higher rates than males (77.08% vs. 60.14%), and young adults aged 25–34 showed the largest increases (from 51.42% to 77.67%). Hispanic (69.17%) and multiracial users (67.25%) exhibited the highest prevalence in 2023. Findings underscore the need for preventive mental health screening and targeted counseling as cannabis legalization expands.

Stroke prehospital time is exceptionally long in China. The multifaceted Stroke 1-2-0 Amplifying Version Engagement (SAVE) intervention has substantially r